Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1313 - Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer


20 Dec 2015


Poster presentation 2


Shoichiro Ohtani


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


S. Ohtani, M. Fujihara

Author affiliations

  • Department Of Breast Surgery, Hiroshima City Hospital, 730-8518 - Hiroshima/JP


Abstract 1313


Capecitabine (X) and Cyclophosphamide (C) are active in MBC patients, have non-overlapping toxic effects and synergy pre-clinically. In this study, we retrospectively evaluated the efficacy and safety of a metronomic oral combination of XC therapy in patients with HER2-negative metastatic breast cancer at our institution.


A retrospective review was conducted of human epidermal growth factor receptor (HER) 2-negative patients with MBC who received XC therapy at Hiroshima City Hospital. Adverse events, time to progression (TTP), and overall survival (OS) were used to evaluate the clinical response to metronomic XC therapy. A dose of 1657 mg/m2/day capecitabine and 65 mg/m2/day cyclophosphamide was given orally twice daily for 14 days. The treatment was repeated at 3-week intervals until disease progression or treatment interruption due to adverse events.


Between 2009 and 2015, we analyzed 71 patients with MBC (median age, 56), with a median previous chemotherapy regimen (range 3). The overall response rate (RR) was 40.3%. The median TTP was 273 days [95% confidence interval (CI), 224–363 days) and median OS was 1045 days (95% CI, 665–1749 days). Of note, median TTP and RR was 247 days and 33.3% in patients with anthracycline- and taxane- pretreated, whereas 328 days and 46.9% in patients without their regimens (p = 0.1571). Further, 40 patients with progression disease with XC therapy were administered next therapy. CR was achieved in 3 (Paclitaxel + Bevacizumab, Tamoxfen + LH-RHa, TS-1), PR was in 5 (Eribulin, Capecitabine, TS-1) and response rate was 20%. Grade 3 or 4 leukopenia was observed in 12 cases (16.9%), neutropenia in 10 (14.1%), anemia in 3 (4.2%), and thrombocytopenia in 0 cases (0%). Non-hematological toxicities were mild. HFS was observed in 14 cases (19.7%), although no cases of grade 4 HFS occurred. Only two patients with grade 3 hemorrhagic cystitis interrupted therapy due to adverse events.


Oral XC therapy was very effective with less toxicity in HER2-negative MBC. This metronomic oral combination could be beneficial for the treatment of HER2 negative MBC in light of quality of life, and preference of MBC patients.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings